Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients."

Diabetes Care. 2002 Oct;25(10):1899-900. doi: 10.2337/diacare.25.10.1899-a.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / economics
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / economics
  • Humans
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*
  • Lactones / economics
  • Lactones / therapeutic use*
  • Obesity*
  • Orlistat

Substances

  • Hypoglycemic Agents
  • Lactones
  • Orlistat